Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Starts US Trial of CD47/PD-L1 Bispecific Antibody

publication date: Mar 2, 2021

Innovent Bio of Suzhou started a US Phase I trial of its anti-CD47/PD-L1 bispecific antibody as a second-line therapy for patients with advanced malignancies. According to Innovent, IBI322 binds to tumor cells more selectively than anti-CD47 monoclonal antibodies, reducing the possibility of binding to CD47 on red blood cells. This feature could reduce the toxicity associated with anti-CD47 antibodies and offer greater antitumor activity. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.